De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients

Table 1 Characteristics of patients at baseline, median (min-max)

Characteristic	De novo combination group (n = 10)	Add-on combination group (n = 20)	P value
Age (yr)	45.6 ± 8.2	45.2 ± 8.2	0.89
Gender (males,%)	6 (60%)	11 (55%)	1
Height (m)	1.7 ± 0.7	1.7 ± 0.9	0.58
Weight (kg)	68.9 ± 9.7	67.3 ± 10.5	0.69
BMI (kg/m2)	23.8 ± 1.8	23.7 ± 1.6	0.88
HBV DNA levels (log10, copies/mL)	6.23 ± 0.91	6.43 ± 0.95	0.58
Serum ALT (IU/L)	124 (82-156)	283 (187-321)	0
Serum TBIL (μmol/L)	49.5 (23-72)	73.5 (49.0-99.6)	0.001
Serum ALB (g/L)	29.75 (25.40-34.00)	26.65 (23.00-32.00)	0.021
Child-Pugh score	11 (9-13)	11 (9-13)	0.809
Red blood cell counts (× 1012/L)	3.6 (3.0-4.5)	3.3 (1.9-5.0)	0.234
HB (g/L)	106 (90-120)	97 (75-115)	0.059
White blood cell counts (× 109/L)	3.85 (2.70-6.80)	3.75 (1.90-6.00)	0.657
Blood PLT count (× 109/L)	96 (76-150)	96 (50-112)	0.657
Serum BUN (mmol/L)	6.05 (3.70-8.10)	4.35 (1.90-8.50)	0.139
Serum Cr (μmol/L)	99.5 (77.0-145.0)	77.0 (40.0-156.0)	0.024

BMI: Body mass index; HBV: Hepatitis B virus; ALT: Alanine aminotransferase; TBIL: Total bilirubin; ALB: Albumin; HB: Hemoglobin; PLT: Platelet; BUN: Blood urine nitrogen; Cr: Creatinine.